

Cheryl A London

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1707275/publications.pdf>

Version: 2024-02-01

57
papers

3,033
citations

185998

28
h-index

155451

55
g-index

59
all docs

59
docs citations

59
times ranked

2805
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Tj ETQq1 1 0.784314 rgBTJ/Overl | 3.2 | 331 |
| 2 | Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. <i>Clinical Cancer Research</i> , 2003, 9, 2755-68. | 3.2 | 212 |
| 3 | Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. <i>Experimental Hematology</i> , 1999, 27, 689-697. | 0.2 | 203 |
| 4 | Comparison of Thoracic Radiographs and Single Breathâ€”Hold Helical CT for Detection of Pulmonary Nodules in Dogs with Metastatic Neoplasia. <i>Journal of Veterinary Internal Medicine</i> , 2006, 20, 508-515. | 0.6 | 140 |
| 5 | Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. <i>American Journal of Veterinary Research</i> , 2002, 63, 1718-1723. | 0.3 | 130 |
| 6 | Tyrosine Kinase Inhibitors in Veterinary Medicine. <i>Topics in Companion Animal Medicine</i> , 2009, 24, 106-112. | 0.4 | 125 |
| 7 | Treatment of Canine Mast Cell Tumors with CCNU (Lomustine). <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 601-605. | 0.6 | 120 |
| 8 | Lomustine (CCNU) for the Treatment of Resistant Lymphoma in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 395-398. | 0.6 | 116 |
| 9 | Perspectives from manâ€™s best friend: National Academy of Medicineâ€™s Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5. | 5.8 | 108 |
| 10 | The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. <i>Experimental Hematology</i> , 2008, 36, 1266-1277. | 0.2 | 103 |
| 11 | Characterization of STAT3 activation and expression in canine and human osteosarcoma. <i>BMC Cancer</i> , 2009, 9, 81. | 1.1 | 98 |
| 12 | Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. <i>Clinical Cancer Research</i> , 2003, 9, 5729-34. | 3.2 | 91 |
| 13 | Evaluation of a Discontinuous Treatment Protocol (VELCAPâ€™S) for Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2001, 15, 348-354. | 0.6 | 90 |
| 14 | Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study. <i>PLoS ONE</i> , 2014, 9, e87585. | 1.1 | 79 |
| 15 | Comparison of COAP and UWâ€™19 Protocols for Dogs with Multicentric Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2007, 21, 1355-1363. | 0.6 | 78 |
| 16 | Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. <i>Communications Biology</i> , 2019, 2, 266. | 2.0 | 77 |
| 17 | The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1018-1028. | 1.9 | 75 |
| 18 | The novel HSP90 inhibitor STAâ€™1474 exhibits biologic activity against osteosarcoma cell lines. <i>International Journal of Cancer</i> , 2009, 125, 2792-2801. | 2.3 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Treatment of canine mast cell tumors with CCNU (lomustine). <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 601-5. | 0.6 | 56 |
| 20 | Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. <i>PLoS ONE</i> , 2015, 10, e0124889. | 1.1 | 51 |
| 21 | Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0159607. | 1.1 | 49 |
| 22 | Classical NF- κ B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. <i>Frontiers in Oncology</i> , 2018, 8, 104. | 1.3 | 49 |
| 23 | Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer. <i>PLoS ONE</i> , 2011, 6, e27018. | 1.1 | 40 |
| 24 | Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. <i>Journal of Veterinary Internal Medicine</i> , 1999, 13, 395-8. | 0.6 | 40 |
| 25 | Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. <i>BMC Cancer</i> , 2017, 17, 67. | 1.1 | 39 |
| 26 | Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. <i>BMC Veterinary Research</i> , 2015, 11, 131. | 0.7 | 36 |
| 27 | MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. <i>BMC Cancer</i> , 2016, 16, 784. | 1.1 | 32 |
| 28 | Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. <i>Cancer Immunology Research</i> , 2018, 6, 671-684. | 1.6 | 29 |
| 29 | VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. <i>Current Oncology Reports</i> , 2022, 24, 463-474. | 1.8 | 28 |
| 30 | MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. <i>PLoS ONE</i> , 2018, 13, e0190086. | 1.1 | 27 |
| 31 | Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. <i>BMC Veterinary Research</i> , 2015, 11, 206. | 0.7 | 26 |
| 32 | Use of Kit Internal Tandem Duplications to Establish Mast Cell Tumor Clonality in 2 Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 915-917. | 0.6 | 23 |
| 33 | Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. <i>BMC Veterinary Research</i> , 2018, 14, 250. | 0.7 | 23 |
| 34 | Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. <i>BMC Veterinary Research</i> , 2012, 8, 244. | 0.7 | 21 |
| 35 | Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. <i>Molecular Biology and Evolution</i> , 2020, 37, 11-17. | 3.5 | 20 |
| 36 | Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. <i>Oncotarget</i> , 2018, 9, 22693-22702. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Kinase dysfunction and kinase inhibitors. <i>Veterinary Dermatology</i> , 2013, 24, 181. | 0.4 | 17 |
| 38 | Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. <i>BMC Veterinary Research</i> , 2014, 10, 160. | 0.7 | 17 |
| 39 | Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. <i>PLoS ONE</i> , 2017, 12, e0181885. | 1.1 | 16 |
| 40 | Phase I/II evaluation of RV1001, a novel PI3K \hat{I} inhibitor, in spontaneous canine lymphoma. <i>PLoS ONE</i> , 2018, 13, e0195357. | 1.1 | 15 |
| 41 | Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0142007. | 1.1 | 13 |
| 42 | Characterization and modulation of canine mast cell derived eicosanoids. <i>Veterinary Immunology and Immunopathology</i> , 2010, 135, 118-127. | 0.5 | 12 |
| 43 | Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. <i>BMC Veterinary Research</i> , 2017, 13, 294. | 0.7 | 12 |
| 44 | Targeted Therapies in Veterinary Oncology. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 917-931. | 0.5 | 12 |
| 45 | Evaluation of a Discontinuous Treatment Protocol (VELCAP-S) for Canine Lymphoma. <i>Journal of Veterinary Internal Medicine</i> , 2001, 15, 348. | 0.6 | 12 |
| 46 | The effects of preoperative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. <i>Canadian Veterinary Journal</i> , 2015, 56, 817-22. | 0.0 | 11 |
| 47 | Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 6396-6407. | 3.2 | 10 |
| 48 | Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29188. | 0.8 | 7 |
| 49 | Identification of Genetic Susceptibility Factors Associated with Canine Gastric Dilatation-Volvulus. <i>Genes</i> , 2020, 11, 1313. | 1.0 | 6 |
| 50 | Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study. <i>BMC Veterinary Research</i> , 2019, 15, 291. | 0.7 | 3 |
| 51 | Plasma cytokeratin \hat{I} 8 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 2061-2068. | 0.6 | 2 |
| 52 | A CTSA One Health Alliance (COHA) survey of clinical trial infrastructure in North American veterinary institutions. <i>BMC Veterinary Research</i> , 2021, 17, 90. | 0.7 | 2 |
| 53 | Comparison of harmonic blade versus traditional approach in canine patients undergoing spinal decompressive surgery for naturally occurring thoracolumbar disk extrusion. <i>PLoS ONE</i> , 2017, 12, e0172822. | 1.1 | 2 |
| 54 | The Role of Small Molecule Inhibitors for Veterinary Patients. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2007, 37, 1121-1136. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Abstract 4700: The novel and selective PI3K \hat{I} inhibitor, RV1001, displays single agent biologic activity in spontaneous canine NHL. , 2015, , . | | 1 |
| 56 | Characterizing the metabolic role of STAT3 in canine osteosarcoma. Veterinary and Comparative Oncology, 0, , . | 0.8 | 1 |
| 57 | Leveraging dogs with spontaneous cancer to advance drug development. , 2019, , 343-372. | | 0 |